Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + epirubicin
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lenvatinib + epirubicin is an investigational combination therapy comprising the multi-kinase inhibitor lenvatinib and the anthracycline chemotherapy agent epirubicin. Lenvatinib functions by inhibiting several receptor tyrosine kinases, including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET, thereby suppressing tumor angiogenesis and proliferation. Epirubicin exerts its cytotoxic effect by intercalating into DNA and inhibiting topoisomerase II, which leads to DNA strand breaks and apoptosis. This combination is primarily being developed by The Second Affiliated Hospital of Air Force Medical University for the treatment of radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), aiming to improve outcomes in patients who have failed standard treatments.
- Other names
- lenvatinib plus epirubicin
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TOP2A (DNA topoisomerase II)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + epirubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + epirubicin.